Major shareholder announcement
Feb 11, 2020
Orphazyme A/S (ORPHA.CO), a biopharmaceutical company pioneering Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, hereby announces the receipt of notification pursuant to Section 38 of the Danish Capital Markets Act from Danske Bank A/S that Danske Bank as of February 7, 2020 holds a total 1,109,876 shares in the Company, corresponding to 5.54% of the share capital and that Danske Bank as of February 7, 2020 controls 8.07% of the voting rights in the Company.
Major shareholder announcement
Read moreOrphazyme completes registration of share capital increases of an aggregated nominal value of DKK 7,032,937
Feb 11, 2020
Orphazyme A/S (ORPHA.CO), a biopharmaceutical company pioneering Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announces that the registration of share capital increases of an aggregated nominal value of DKK 7,032,937 has been completed.
Orphazyme completes registration of share capital
Read moreAnnouncement of treasury shares
Feb 7, 2020
Orphazyme A/S (ORPHA.CO), a biopharmaceutical company pioneering Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, hereby announces with reference to the completed offering of 7,032,937 new shares and existing shares in a directed issue and private placement as announced by company announcement no. 12/2020 on February 7, 2020 that Orphazyme as of today no longer holds any treasury shares.
Announcement of treasury shares
Read moreOrphazyme completes offering of 7,032,937 shares in a directed issue and private placement and raises approximately DKK 745,000,000 (EUR 100 million/USD 110 million)
Feb 7, 2020
Orphazyme A/S (ORPHA.CO), a biopharmaceutical company pioneering Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announces the completion of an offering of 7,032,937 new shares and existing shares in a directed issue and private placement raising gross proceeds of approximately DKK 745,000,000.
Orphazyme completes offering of 7 032 937 shares
Read moreAnnouncement of treasury shares
Feb 6, 2020
Orphazyme A/S (ORPHA.CO), a biopharmaceutical company pioneering Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, hereby announces that pursuant to Section 31 of the Danish Capital Markets Act Orphazyme holds 3,071,673 treasury shares of DKK 1 each corresponding to 15.35 % of the total share capital and voting rights of Orphazyme as of today.
Announcement of treasury shares
Read moreReporting of transactions in Orphazyme’s shares
Feb 6, 2020
Orphazyme A/S (ORPHA.CO), a biopharmaceutical company pioneering Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, hereby notifies receipt of the attached information of transactions in Orphazyme’s shares by a person closely associated with a person discharging managerial responsibilities in Orphazyme pursuant to Article 19 of the Market Abuse Regulation.
Reporting of transactions in Orphazymes shares
Notification Orpha pooling person closely associated ...
Read moreMajor shareholder announcement
Feb 6, 2020
Orphazyme A/S (ORPHA.CO), a biopharmaceutical company pioneering Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, hereby notifies receipt of the attached major shareholder notifications pursuant to Section 38 of the Danish Capital Markets Act.
Major shareholder letter to Orphazyme
Major shareholder letter to Orphazyme as Novo Nordisk fonden
Major shareholder announcement
Read moreOrphazyme initiates directed issue and private placement of shares
Feb 6, 2020
Orphazyme A/S (ORPHA.CO), a biopharmaceutical company pioneering Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announces that the Board of Directors has resolved to initiate a directed issue and private placement of up to an aggregate of 7,032,937 new shares and existing shares, at market price as determined by the Board of Directors of the Company through a book-building process, corresponding to approximately 35.16% of the Company’s currently registered share capital.
Orphazyme initiates directed issue and private place
Read morePreliminary results for 2019 and financial outlook for 2020
Feb 4, 2020
Orphazyme A/S (ORPHA.CO), a biopharmaceutical company pioneering Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today releases preliminary results for 2019 as well as the financial outlook for 2020.
Preliminary results for 2019 and financial outlook
Read moreCapital increase of 20,650 shares (equivalent to approximately 0.10% of the existing shares) in Orphazyme A/S as a result of an issue of bonus shares to KLSDC and UCLB
Jan 31, 2020
Orphazyme A/S (ORPHA.CO), a biopharmaceutical company pioneering Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today decided on a capital increase as a result of a directed issue of bonus shares to Kansas Life Sciences Development Company, Inc. (“KLSDC”) and UCL Business Ltd. (“UCLB”). The capital increase was decided pursuant to the Board of Directors’ authorization laid down in Article 3.6 of the Articles of Association.
Capital increase of 20650 shares in Orphazyme
Read more